Introduction The efficacy and safety profile of ustekinumab (UST) in Crohn's disease (CD) is
favorable; however, data in elderly patients are lacking. We aimed to assess the safety and …

Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased
infection risk among elderly inflammatory bowel disease (IBD) patients and thus alternative …

Abstract Background and Aims Clinical trials and real-life studies with ustekinumab in
Crohn's disease [CD] have revealed a good efficacy and safety profile. However, these data …

Abstract Background The burden of Inflammatory Bowel Disease (IBD) in elderly patients
derives from background comorbidities and the elevated risk associated with …

Background Clinical trials and real-life studies with Ustekinumab in Crohn's disease show its
good efficacy and safety profile. However, there are hardly any data on elderly patients, who …

METHODS: We performed a retrospective analysis of CD patients treated at a large, tertiary
referral center, who received UST for treatment of CD. We obtained data on demographics …

Background The rising incidence of inflammatory bowel disease (IBD) worldwide and an
ageing population has led to a marked increase in elderly IBD patients. Anti-tumour necrosis …

Introduction The rising incidence of inflammatory bowel disease (IBD) worldwide and an
ageing population has led to a marked increase in elderly IBD patients. Anti-tumour necrosis …

Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased
infection risk among elderly inflammatory bowel disease (IBD) patients and thus alternative …

Objective Anti-tumour necrosis factor (TNF) agents are associated with increased infection
risk among elderly IBD patients, but little is known about non anti-TNF biologics in this …